FDA Class II Recall: Glenmark's Carvedilol Tablets Hit by Nitrosamine Impurity
Glenmark Pharmaceuticals Inc., USA has initiated a Class II recall for multiple lots of its Carvedilol Tablets, USP, 12.5 mg, distributed nationwide. The action, D-0216-2025, stems from Current Good Manufacturing Practice (CGMP) deviations, specifically the presence of N-Nitroso Carvedilol I (NNCI-I) impurity exceeding FDA-recommended limits. This voluntary recall highlights critical nitrosamine contamination risks, demanding immediate attention from procurement, regulatory, and supply chain leaders to assess inventory and supplier qualification.
FDA Class II Recall: Glenmark's Carvedilol Tablets Impacted by Nitrosamine Impurity
Glenmark Pharmaceuticals Inc., USA, headquartered in Mahwah, NJ, United States (postal code 07430-2009), has initiated a voluntary Class II recall, designated D-0216-2025, for multiple lots of its Carvedilol Tablets, USP, 12.5 mg, Rx only. The recall, initiated on January 22, 2025, is a direct consequence of Current Good Manufacturing Practice (CGMP) deviations, specifically the detection of N-Nitroso Carvedilol I (NNCI-I) impurity at levels exceeding the current FDA recommended limit. This action affects Carvedilol Tablets distributed nationwide in the U.S., impacting both 500-tablet bottles (NDC 68462-164-05) and 100-tablet bottles (NDC 68462-164-01). Procurement directors and supply chain VPs must immediately identify and quarantine affected inventory. Specifically, the recall targets numerous lots with expiry dates ranging from February 2025 to February 2026. Key affected lots for 500-tablet bottles include 17230658 (Exp.: 02/2025); 17230814, 17230822 (Exp.: 03/2025); 17231004, 17231009, 17231022 (Exp.: 04/2025); 17231393, 17231392 (Exp.: 05/2025); 17231538, 17231541, 17231542 (Exp.: 06/2025); 17231710, 17231718, 17231721, 17231722, 17231730 (Exp.: 07/2025); 17232169 (Exp.: 09/2025); 17232253 (Exp.: 10/2025); 17240220, 17240240 (Exp.: 01/2026); and 17240459 (Exp.: 02/2026). For 100-tablet bottles, affected lots include 17230814 (Exp.: 03/2025); 17231392 (Exp.:05/2025); and 17232260 (Exp.: 10/2025). Regulatory affairs heads must ensure all internal and downstream partners, including wholesalers, pharmacies, and healthcare providers, are promptly notified and adhere to recall protocols to mitigate further distribution of non-compliant product.
Navigating Nitrosamine Contamination Risks in Generic Drug Supply Chains
The presence of N-Nitroso Carvedilol I (NNCI-I) impurity in Glenmark's Carvedilol Tablets underscores an industry-wide challenge with nitrosamine contamination. Since 2018, the FDA has intensified its scrutiny of nitrosamine impurities, which are classified as probable human carcinogens, across various drug products. This recall highlights that even established generic manufacturers face significant hurdles in controlling these genotoxic impurities, which can originate from raw materials, manufacturing processes, or degradation over time. For quality assurance and regulatory affairs teams, this event necessitates a comprehensive re-evaluation of current Good Manufacturing Practice (CGMP) adherence, particularly concerning impurity profiles and analytical testing methodologies. Companies must implement robust nitrosamine risk assessment frameworks, covering all active pharmaceutical ingredients (APIs) and excipients. This includes conducting thorough supplier audits to verify their control strategies for nitrosamine formation and investing in advanced analytical techniques, such as liquid chromatography-mass spectrometry (LC-MS/MS), capable of detecting these impurities at trace levels. Failure to proactively manage these risks can lead to costly recalls, regulatory enforcement actions, and significant reputational damage, impacting market access and patient trust. Supply chain VPs should consider this a critical signal to enhance their due diligence on ingredient sourcing and manufacturing process controls across their entire portfolio.
Commercial Ramifications for Carvedilol Supply and Market Stability
Carvedilol, a crucial alpha- and beta-adrenergic blocker, is widely prescribed for managing essential hypertension and heart failure. The nationwide Class II recall of Glenmark Pharmaceuticals Inc., USA's 12.5 mg Carvedilol Tablets, impacting numerous lots, will inevitably create a disruption in the supply chain for this specific dosage strength. While the full market impact depends on Glenmark's specific market share and the capacity of other manufacturers to absorb demand, procurement directors must immediately assess their current inventory levels and identify alternative qualified suppliers for Carvedilol to prevent potential stock-outs and ensure continuity of patient care. For business development executives, this situation presents a dual challenge and opportunity. Companies with robust quality systems and a demonstrated history of regulatory compliance in their Carvedilol supply may experience increased demand as buyers seek reliable alternatives. Conversely, it underscores the critical need for diversified sourcing strategies and agile supply chain management to mitigate risks associated with single-source dependencies or quality issues from major suppliers. The incident reinforces the commercial imperative of maintaining impeccable quality and regulatory compliance, not only to secure market position but also to uphold public health and avoid significant financial and reputational repercussions.